Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels

키워드

참고문헌 (64)

1. Allen AM, "Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death : a 20 year-community study", Hepatology, 67, pp.1726~1736 (2018)
2. Sanyal AJ, "Nonalcoholic steatohepatitis : association of insulin resistance and mitochondrial abnormalities", Gastroenterology, 120, pp.1183~1192 (2001)
3. Williams CD, "Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy : a prospective study", Gastroenterology, 140, pp.124~131 (2011)
4. Lomonaco R, "Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes", Diabetes Care, 39, pp.632~638 (2016)
5. Rena G, "The mechanisms of action of metformin", Diabetologia, 60, pp.1577~1585 (2017)
6. Li Y, "Metformin in nonalcoholic fatty liver disease : a systematic review and metaanalysis", Biomed Rep, 1, pp.57~64 (2013)
7. Haukeland JW, "Metformin in patients with non-alcoholic fatty liver disease : a randomized, controlled trial", Scand J Gastroenterol, 44, pp.853~860 (2009)
8. Uygun A, "Metformin in the treatment of patients with non-alcoholic steatohepatitis", Aliment Pharmacol Ther, 19, pp.537~544 (2004)
9. Bugianesi E, "A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease", Am J Gastroenterol, 100, pp.1082~1090 (2005)
10. Duseja A, "Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease(NAFLD)not responding to lifestyle interventions", Ann Hepatol, 6, pp.222~226 (2007)
11. Nair S, "Metformin in the treatment of non-alcoholic steatohepatitis : a pilot open label trial", Aliment Pharmacol Ther, 20, pp.23~28 (2004)
12. Shields WW, "The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic ateatohepatitis(NASH) : a pilot trial", Therap Adv Gastroenterol, 2, pp.157~163 (2009)
13. Song YM, "Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway", Autophagy, 11, pp.46~59 (2015)
14. Fullerton MD, "Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin", Nat Med, 19, pp.1649~1654 (2013)
15. Ford RJ, "Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity", Biochem J, 468, pp.125~132 (2015)
16. Huang H, "Rho-kinase", AMPK axis regulates hepatic lipogenesis during overnutrition, 2018, pp.128, 5335~5350
17. Sanders FW, "De novo lipogenesis in the liver in health and disease : more than just a shunting yard for glucose", Biol Rev Camb Philos Soc, 91, pp.452~468 (2016)
18. Brownsey RW, "Regulation of acetyl-CoA carboxylase", Biochem Soc Trans, 34(Pt 2), pp.223~227 (2006)
19. Viollet B, "Activation of AMPactivated protein kinase in the liver : a new strategy for the management of metabolic hepatic disorders", J Physiol, 574(Pt 1), pp.41~53 (2006)
20. Li YL, "Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in vitro and in vivo", Biochem Biophys Res Commun, 513, pp.64~72 (2019)
21. Geng Y, "Protective effect of metformin against palmitate-induced hepatic cell death", Biochim Biophys Acta Mol Basis Dis, 1866, pp.165621~ (2020)
22. Guo J, "Metformin-induced changes of the coding transcriptome and non-coding RNAs in the livers of non-alcoholic fatty liver disease mice", Cell Physiol Biochem, 45, pp.1487~1505 (2018)
23. Tang X, "Metformin increases hepatic leptin receptor and decreases steatosis in mice", J Endocrinol, 230, pp.227~237 (2016)
24. Karavia EA, "Deficiency in apolipoprotein A-I ablates the pharmacological effects of metformin on plasma glucose homeostasis and hepatic lipid deposition", Eur J Pharmacol, 766, pp.76~85 (2015)
25. Khalaf HM, "Allopurinol potentiates the hepatoprotective effect of metformin and vitamin E in fructoseinduced fatty liver in rats", Clin Exp Hepatol, 5, pp.65~74 (2019)
26. Brandt A, "Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine", Sci Rep, 9, pp.6668~ (2019)
27. Shin NR, "Flos Lonicera combined with metformin ameliorates hepatosteatosis and glucose intolerance in association with gut microbiota modulation", Front Microbiol, 8, pp.2271~ (2017)
28. de Jesús Acosta-Cota S, "Therapeutic effect of treatment with metformin and", or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease, 2019, pp.863, 172699~
29. Mahzari A, "Matrine protects against MCD-induced development of NASH via upregulating HSP72 and downregulating mTOR in a manner distinctive from metformin", Front Pharmacol, 10, pp.405~ (2019)
30. Sui Y, "Long-term treatment with metformin in the prevention of fatty liver in Zucker diabetic fatty rats", Diabetol Metab Syndr, 11, pp.94~ (2019)
31. Matafome P, "Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia", Diabetes Metab Res Rev, 27, pp.54~62 (2011)
32. Hawley SA, "The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism", Diabetes, 51, pp.2420~2425 (2002)
33. Li Y, "AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice", Cell Metab, 13, pp.376~388 (2011)
34. Polyzos SA, "Leptin in nonalcoholic fatty liver disease : a narrative review", Metabolism, 64, pp.60~78 (2015)
35. Polyzos SA, "Circulating leptin in non-alcoholic fatty liver disease : a systematic review and meta-analysis", Diabetologia, 59, pp.30~43 (2016)
36. Fishman S, "Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo", FASEB J, 21, pp.53~60 (2007)
37. Yokoi N, "A novel rat model of type 2 diabetes : the Zucker Fatty Diabetes Mellitus ZFDM rat", J Diabetes Res, 2013, pp.103731~ (2013)
38. Stachowicz A, "Proteomic analysis of liver mitochondria of apolipoprotein E knockout mice treated with metformin", J Proteomics, 77, pp.167~175 (2012)
39. Bradham CA, "Mechanisms of hepatic toxicity. I. TNF-induced liver injury", Am J Physiol, 275, pp.G387~ (1998)
40. Kakino S, "Pivotal role of TNF-αin the development and progression of nonalcoholic fatty liver disease in a murine model", Horm Metab Res, 50, pp.80~87 (2018)
41. Singh R, "Autophagy and regulation of lipid metabolism", Results Probl Cell Differ, 52, pp.35~46 (2010)
42. You L, "The role of STAT3 in autophagy", Autophagy, 11, pp.729~739 (2015)
43. Karavia EA, "Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice", Mol Med, 18, pp.901~912 (2012)
44. Martínez-Chantar ML, "Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice", Hepatology, 47, pp.1191~1199 (2008)
45. Bäckhed F, "The gut microbiota as an environmental factor that regulates fat storage", Proc Natl Acad Sci U S A, 101, pp.15718~15723 (2004)
46. Zhang R, "Metformin and diammonium glycyrrhizinate enteric-coated capsule versus metformin alone versus diammonium glycyrrhizinate enteric-coated capsule alone in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus", Gastroenterol Res Pract, 2017, pp.8491742~ (2017)
47. Fan H, "Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease", Arq Bras Endocrinol Metabol, 57, pp.702~708 (2013)
48. Feng W, "Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease", J Diabetes, 9, pp.800~809 (2017)
49. Yabiku K, "Effects of oral antidiabetic drugs on changes in the liver-to-spleen ratio on computed tomography and inflammatory biomarkers in patients with type 2 diabetes and nonalcoholic fatty liver disease", Clin Ther, 39, pp.558~566 (2017)
50. Tian F, "Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease", Biosci Rep, 38, pp.BSR2018130~ (2018)
51. Omer Z, "Efficacy of insulinsensitizing agents in nonalcoholic fatty liver disease", Eur J Gastroenterol Hepatol, 22, pp.18~23 (2010)
52. Shibuya T, "Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease : a prospective randomized controlled pilot study", Diabetes Obes Metab, 20, pp.438~442 (2018)
53. Zsóri G, "In new-onset diabetes mellitus, metformin reduces fat accumulation in the liver, but not in the pancreas or pericardium", Metab Syndr Relat Disord, 17, pp.289~295 (2019)
54. Wang DS, "Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin", J Pharmacol Exp Ther, 302, pp.510~515 (2002)
55. Morse BL, "Pharmacokinetics of Organic Cation Transporter 1(OCT1)substrates in Oct1", 2knockout mice and species difference in hepatic OCT1-mediated uptake, 2020, pp.48, 93~105
56. Cuthbertson DJ, "Improved glycaemia correlates with liver fat reduction in obese, type 2diabetes, patients given glucagon-like peptide-1(GLP-1)receptor agonists", PLoS One, 7, pp.e50117~ (2012)
57. Yan J, "Liraglutide, sitagliptin, and insulin glargine added to metformin : the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease", Hepatology, 69, pp.2414~2426 (2019)
58. 최덕현, "Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease", Endocrinology and Metabolism, 33(3), pp.387~394 (2018), 대한내분비학회
59. Singh S, "Antidiabetic medications and the risk of hepatocellular cancer : a systematic review and meta-analysis", Am J Gastroenterol, 108, pp.881~891 (2013)
60. Noto H, "Cancer risk in diabetic patients treated with metformin : a systematic review and meta-analysis", PLoS One, 7, pp.e33411~ (2012)
61. Kim HJ, "Metformin reduces the risk of cancer in patients with type 2 diabetes: an analysis based on the Korean National Diabetes Program Cohort", Medicine (Baltimore), 97, pp.e0036~ (2018)
62. Tseng CH, "Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes", Liver Int, 38, pp.2018~2027 (2018)
63. Tajima K, "Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl", 6mice, 2013, pp.305, E987~
64. de Oliveira S, "Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish", J Hepatol, 70, pp.710~721 (2019)